liklihood for trading halt, page-6

I am betting it is good news. I cannot see the TGA obstructing the clinical trial too much longer. Terminal patients need other options and Coramsine has already demonstrated some efficacy against RCC(kidney cancer) in the Phase 1 trial. I hope this trial gets back on track ASAP.
At these low prices I think there will be a fairly sharp upward revaluation of Solbecs market cap once we can see the future direction with the trials back on line. As I recall, Solbec said they would release intrim results as the trial progresses.
It is easy to think of Solbec as just another tiny local biotech, but with results in hand from the phase 1 trial Solbec is head and shoulders above the field here in Australia. NO other biotech in Australia, regardless of size, has had phase 1 clinical trial results for a drug in terminal cancers to match what Coramsine has produced IMHO.
Does anybody have any info on the Psorisis treatment? Since the original trial was shown to be flawed, are there plans to go ahead with another trial? I think this is still an area that could add value to SBP.
I guess we could be going to hear about ongoing finance options.
Good luck to holders